What is supported in animal models Increased lipolysis, increased fat oxidation, decreased lipogenesis, no apparent effect on plasma glucose or insulin sensitivity, and signal that intact beta-3 adrenergic receptor activity matters for the fat-loss effect
Is BPC-157 approved by Health Canada It is not approved by Health Canada outside of approved research and laboratory settings
Since NNMT is expressed in adipose, hepatic, and gut tissues 50,51,52 , and these tissues heavily cross-talk with the gut microbiome 53,54,55 , NNMTi treatment or its resulting weight loss effects 8,9 may modulate the microbiome
The recommendation is not binding
Petersen JA, Wilm BJ, von Meyenburg J, Schubert M, Seifert B, Najafi Y, et al
Dihexa is studied for its proposed capacity to function as a potentiator of hepatocyte growth factor (HGF) at the MET receptor tyrosine kinase, rather than acting as a direct receptor agonist